Prescribing biosimilars.

BMJ

West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham, UK.

Published: July 2018

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmj.k3141DOI Listing

Publication Analysis

Top Keywords

prescribing biosimilars
4
prescribing
1

Similar Publications

Objective This study aims to evaluate the real-world efficacy of ranibizumab biosimilar (Ongavia), compared to aflibercept (Eylea), in the treatment of treatment-naïve neovascular age-related macular degeneration (nAMD) at a busy tertiary eye care centre. Methods A retrospective analysis of medical records from August 2022 to August 2024 was conducted, comparing treatment outcomes in treatment-naive nAMD patients who received either Ongavia or Eylea intravitreal anti-VEGF (vascular endothelial growth factor) injections under a treat-and-extend protocol. Initial and 12-month outcome measures post-treatment initiation were collected, including best-corrected visual acuity (BCVA), central retinal thickness (CRT), prescribed treatment intervals, actual injection frequency, and the average total number of injections per eye over 12 months.

View Article and Find Full Text PDF
Article Synopsis
  • The paper reviews various cost containment policies aimed at controlling pharmaceutical spending by either regulating the industry or influencing consumer demand.
  • A narrative literature review highlights that governments have adopted diverse strategies like cost-sharing, value-based pricing, and the promotion of generics, but their effectiveness varies between healthcare systems and can negatively affect patients.
  • The conclusion emphasizes the need for thorough evaluation of these policies to ensure their success, as many lack strong evidence of cost-effectiveness and suggest that further research is essential to create tailored solutions that maintain affordability, fairness, and sustainability in healthcare.
View Article and Find Full Text PDF

Introduction Biologics are substantial in the treatment of different diseases; however, they can burden the healthcare systems due to their high cost. Biosimilars can help healthcare systems keep their financial sustainability and patients access to biological therapies. The research objective is to formulate a framework for integrating biosimilars in the private healthcare sector of the United Arab Emirates (UAE).

View Article and Find Full Text PDF

Introduction: Opioids and benzodiazepines are commonly prescribed for cancer symptoms. In combination, they can increase the risk of adverse events, particularly for older adults with multimorbidity, who represent most patients with cancer. We aimed to understand cancer care providers' practices for opioid and benzodiazepine coprescribing and mitigating potential harms.

View Article and Find Full Text PDF

Objective: To analyze the variability in new infliximab biosimilar starts as well as switching from bio-originator to biosimilar infliximab, across insurance payers and rheumatology practices nationally.

Study Setting And Design: Data came from Rheumatology Informatics System for Effectiveness, a national registry with electronic health records from over 1100 US rheumatologists. Key outcomes include ever use of a biosimilar, date of initiation, and date of switching.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!